Play all audios:
Correction to: _Scientific Reports_ https://doi.org/10.1038/s41598-019-55666-x, published online 13 December 2019 The original version of this Article contained errors. The P-values for the
comparisons shown in Figure 10 and reported in the text were not controlled for alpha error. We used Hochberg’s method (the modified Bonferroni method) for P-value correction; the main
results remain the same after this correction, but the Article now reports adjusted P-values. The Article changed as follows. The original Figure 10 and accompanying legend appear below. In
the Methods, under the subheading ‘Statistical analysis’, “With regards to survival probability, a log rank (Mantel–Cox) test was performed to assess the significance of differences between
groups in Kaplan–Meier analysis. A value of P < 0.05 was considered to indicate statistical significance.” now reads: “With regards to survival probability, a log rank (Mantel–Cox) test
was performed to assess the significance of differences between groups in Kaplan–Meier analysis. A value of P < 0.05 was considered to indicate statistical significance. The P-values were
adjusted using the Hochberg's method.” In the Results, under the subheading ‘Effect on survival probability’, “The Kaplan–Meier survival curves depicted in Fig. 10 reveal that
DEN-treated model mice had higher mortality rates than MBZ-treated HCC mice (log-rank test P = 0.04, hazard ratio = 2.03) (Fig. 10b), SO-treated HCC mice (log-rank test P = 0.01, hazard
ratio = 2.46) (Fig. 10b), and MBZ + SO-treated HCC mice (log-rank test P < 0.0001, hazard ratio = 7.45) (Fig. 10c), indicating that the drug-treated HCC mice exhibited higher survival
curves and survival % than the DEN-treated model mice. In addition, the MBZ + SO group demonstrated the highest survival probability among the treatment groups, as illustrated in Fig. 10f
(MBZ + SO vs. SO: log-rank test P = 0.04, hazard ratio = 2.91) and Fig. 10e (MBZ + SO vs. MBZ: log-rank test P = 0.01, hazard ratio = 3.62).” now reads: “The Kaplan–Meier survival curves
depicted in Fig. 10 reveal that DEN-treated model mice had higher mortality rates than MBZ-treated HCC mice (log-rank test P-adj = 0.04, hazard ratio = 2.03) (Fig. 10a), SO-treated HCC mice
(log-rank test P-adj = 0.03, hazard ratio = 2.46) (Fig. 10b), and MBZ + SO-treated HCC mice (log-rank test P-adj = 0.0005, hazard ratio = 7.45) (Fig. 10c), indicating that the drug-treated
HCC mice exhibited higher survival curves and survival % than the DEN-treated model mice. In addition, the MBZ + SO group demonstrated the highest survival probability among the treatment
groups, as illustrated in Fig. 10d (MBZ + SO vs. SO: log-rank test P-adj = 0.04, hazard ratio = 2.91) and Fig. 10e (MBZ + SO vs. MBZ: log-rank test P-adj = 0.03, hazard ratio = 3.62).”
Additionally, Figure 10 was revised to include adjusted P-values. The original Article has been corrected. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Pharmaceutical
Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia Nancy S. Younis * Department of Pharmacology, Zagazig University, Zagazig, Egypt Nancy S.
Younis * Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt Amal M. H. Ghanim * Department of Pharmacology, Faculty of Pharmacy,
Delta University for Science and Technology, Gamasa, Egypt Sameh Saber Authors * Nancy S. Younis View author publications You can also search for this author inPubMed Google Scholar * Amal
M. H. Ghanim View author publications You can also search for this author inPubMed Google Scholar * Sameh Saber View author publications You can also search for this author inPubMed Google
Scholar CORRESPONDING AUTHOR Correspondence to Nancy S. Younis. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence,
unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Younis, N.S., Ghanim, A.M.H. & Saber, S. Author Correction: Mebendazole
augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. _Sci Rep_ 12, 13607 (2022).
https://doi.org/10.1038/s41598-022-17580-7 Download citation * Published: 10 August 2022 * DOI: https://doi.org/10.1038/s41598-022-17580-7 SHARE THIS ARTICLE Anyone you share the following
link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature
SharedIt content-sharing initiative